BioFactura Joins Stelara Biosimilar Crowd
US-Based Developer Throws Its Hat Into The Ring For Ustekinumab
Janssen’s Stelara is continuing to attract a growing crowd of proposed biosimilar rivals, with BioFactura becoming the latest to throw its hat into the ring after kicking off Phase I trials for its BFI-751 version.
